Dengue Fever: 2.5 Billion People at Risk Could Be Treated With New Vaccine

Dengue fever is a viral disease, which is transmitted through a vector, typically a mosquito and is present in tropical regions of the world. Currently, there is no vaccine or medicine licensed for treatment, although up to 2.5 billion people in the world are at risk, with 1.8 billion residing in the Asia Pacific Region such as Indonesia, Malaysia and the Philippines.

While vague symptoms such as fever and muscular pain from infection are treated with rest, plenty of fluids and paracetamol like many common viral ailments, severe Dengue can lead to a potentially lethal hemorrhagic fever, which requires intensive medical care.

Vaccine Development:
● There are many promising vaccine developments due to a need in the pipeline, with a live attenuated vaccine from other manufacturers
● Following a phase 3 trial to assess efficacy and safety in Asia-Pacific and Latin America, the vaccine reported 57 % and 60.6 % efficacy respectively for the four variants of the disease, with a proportional increase in efficacy with age reported

At Taj Accura Pharmaceuticals, we believe that optimum patient care is essential, and at the very best cost where possible. We prioritise the most innovative research offered by Taj Pharmaceuticals in Mumbai, as well as working with the most state-of-the-art manufacturers in Europe. We offer a wide range of generic vaccines to date, and strive to provide many more where possible for an overall health and economic benefit.

References:
World Health Organisation ‘Dengue and Severe Dengue Fact Sheet’ 2014
World Health Organisation ‘Q & A on Dengue Vaccines, Phase III Study of CYD-TDV’ November 2014 (Latin America) and July 2014 (Asia-Pacific)Dengue Fever: 2.5 Billion People at Risk Could Be Treated With New Vaccine – Taj Dearob Pharma | Dengue fever is a viral disease, which is transmitted through a vector, typically a mosquito and is present in tropical regions of the world. Currently, there is no vaccine or medicine licensed for treatment, although up to 2.5 billion people in the world are at risk, with 1.8 billion residing in the Asia Pacific Region such as Indonesia, Malaysia and the Philippines.
Dengue Fever: 2.5 Billion People at Risk Could Be Treated With New Vaccine – Taj Dearob Pharma | Dengue fever is a viral disease, which is transmitted through a vector, typically a mosquito and is present in tropical regions of the world. Currently, there is no vaccine or medicine licensed for treatment, although up to 2.5 billion people in the world are at risk, with 1.8 billion residing in the Asia Pacific Region such as Indonesia, Malaysia and the Philippines.
Dengue Fever: 2.5 Billion People at Risk Could Be Treated With New Vaccine – Taj Dearob Pharma | Dengue fever is a viral disease, which is transmitted through a vector, typically a mosquito and is present in tropical regions of the world. Currently, there is no vaccine or medicine licensed for treatment, although up to 2.5 billion people in the world are at risk, with 1.8 billion residing in the Asia Pacific Region such as Indonesia, Malaysia and the Philippines.
Dengue Fever: 2.5 Billion People at Risk Could Be Treated With New Vaccine – Taj Dearob Pharma | Dengue fever is a viral disease, which is transmitted through a vector, typically a mosquito and is present in tropical regions of the world. Currently, there is no vaccine or medicine licensed for treatment, although up to 2.5 billion people in the world are at risk, with 1.8 billion residing in the Asia Pacific Region such as Indonesia, Malaysia and the Philippines.